About: Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.60 (-5.47%)
ARCT NASDAQ Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc share price
Atividade de preço de ARCT
Último preço
$ 7,600
Variação (24h)
-0,44 USD (5,47%)
Volume
462.28K
Volume (média 4 sem.)
-
Abertura
$ 8,06
Variação do dia
$ 7,54 - $ 8,15
Fechamento anterior
$ 8,04
Último negócio
19 Nov, 9:00 pm GMT+0
Atrasado
19 Nov, 9:00 pm GMT+0
ARCT price performance
Atrasado
19 Nov, 9:00 pm GMT+0
ARCT details
quote.marketSignals